Publication: Implications of polygenic risk-stratified screening for prostate cancer on overdiagnosis.
Publication Date: Jan. 8, 2015
Journal: Genet Med
Authors: Pashayan N, Duffy SW, Neal DE, Hamdy FC, Donovan JL, Martin RM, Harrington P, Benlloch S, Amin Al Olama A, Shah M, Kote-Jarai Z, Easton DF, Eeles R, Pharoah PD.
PGS Associated with PGP000032
External PGS Evaluated By This Study
PGS Performance MetricsDisclaimer: The performance metrics are displayed as reported by the source studies. It is important to note that metrics are not necessarily comparable with each other. For example, metrics depend on the sample characteristics (described by the PGS Catalog Sample Set [PSS] ID), phenotyping, and statistical modelling. Please refer to the source publication for additional guidance on performance.
|PGS Performance Metric (PPM) ID||Evaluated Score||PGS Catalog Sample Set (PSS) ID||Performance Source||Trait||
PGS Effect Sizes
(per SD change)
|PGS Classification Metrics||Other Metrics||Covariates Included in PGS Model||PGS Performance: Other Relevant Information|
|PPM000105||PGS000044 (PrCa66)||PSS000069||Pashayan N et al. (2015) Ext.||Reported Trait: aggressive prostate cancer (Gleason score ⩾7)||—||—||OR (above vs. below 50th percentile of PRS): 1.56 [1.15 - 2.1]||—||—|
|PGS Catalog Sample Set (PSS) ID||Detailed Phenotype Description (e.g. ICD/SNOMED codes used to identify cases)||Sample Numbers||Sample Ancestry||Additional Ancestry Description||Cohort(s)||Additional Sample/Cohort Information|
|PSS000069||Prostate cancer was classified as localised disease with tumour-node-metastasis (TNM) stage T1-2 N0 M0; and advanced disease (regional-distant) with stage T3 and above or any T N1 M1; as non-aggressive tumour, Gleason score <7, and aggressive tumour, Gleason score ⩾7.||4,967 individuals
[ 1,089 cases, 3,878 controls]
100.00 %% Male samples